Company:  OMEROS CORP (OMER)
Form Type:  8-K
Filing Date:  8/7/2012 
CIK:  0001285819 
Address:  201 ELLIOTT AVENUE WEST 
City, State, Zip:  SEATTLE, Washington 98119 
Telephone:  206-676-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$12.09  
Change: 
0.24 (2.03%)  
Trade Time: 
Apr 24  
Market Cap: 
$403.84M
Description of Business
We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product, Omidria� for lens replacement surgery, is derived from our proprietary PharmacoSurgery� platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. In addition to Omidria, we have six other clinical-stage development programs in our pipeline.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02 Results of Operation and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
    INCOME STATEMENT
BROKERAGE PARTNERS